Helena Collgros
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Helena Collgros has a total of 144 co-authors. Here are the top co-authors by number of shared publications:
- Pascale Guitera
Melanoma Institute Australia The University of Sydney Sydney New South Wales Australia
8 shared publications - Anne E. Cust
The Daffodil Centre, The University of Sydney, and Cancer Council NSW, Sydney, Australia
6 shared publications P. Umbert-Millet
Departamento de Dermatología, Hospital Universitari Sagrat Cor, Barcelona, España
5 shared publications- Richard Scolyer
Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia
5 shared publications - Amanda Regio Pereira
Sydney Melanoma Diagnostic Centre Royal Prince Alfred Hospital Camperdown Australia
4 shared publications - Bruna Melhoranse Gouveia
Melanoma Institute Australia The University of Sydney Sydney New South Wales Australia
3 shared publications
Latest Publications
- Open Access
- 11 July 2026
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 67 (7)
Optimising Melanoma Diagnostic Accuracy in Specialised Pigmented Lesion Clinics: A Five‐Year Audit of Number Needed to Treat
- 11 July 2026
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 67 (7)
Open AccessOptimising Melanoma Diagnostic Accuracy in Specialised Pigmented Lesion Clinics: A Five‐Year Audit of Number Needed to Treat
- Open Access
- 12 August 2025
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 66 (7) , 388-395
A Clinical Perspective on Melanoma Overdiagnosis
Overdiagnosis in melanoma is a nuanced and evolutionary issue. It may appear to be an epidemic from an epidemiological point of view; however, it is important to appreciate all perspectives. We consider overdiagnosis a necessary challenge—which drives clinicians to improve diagnostic accuracy and reduce overtreatment—pathologists to recalibrate histopathological thresholds and reduce overcalling—and researchers to develop markers of biological activity for melanoma. In this article, we present our clinical perspective on the current burden of melanoma overdiagnosis and its future value for progress in the field of melanoma.
- 12 August 2025
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 66 (7) , 388-395
Open AccessA Clinical Perspective on Melanoma Overdiagnosis
Overdiagnosis in melanoma is a nuanced and evolutionary issue. It may appear to be an epidemic from an epidemiological point of view; however, it is important to appreciate all perspectives. We consider overdiagnosis a necessary challenge—which drives clinicians to improve diagnostic accuracy and reduce overtreatment—pathologists to recalibrate histopathological thresholds and reduce overcalling—and researchers to develop markers of biological activity for melanoma. In this article, we present our clinical perspective on the current burden of melanoma overdiagnosis and its future value for progress in the field of melanoma.
- 13 February 2025
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 145 (8) , 2108-2111.e5
Integrated Analysis of Proteomic and Dermoscopy Imaging Data Improves Noninvasive Classification of Benign Nevi and Melanoma
- 13 February 2025
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 145 (8) , 2108-2111.e5
Integrated Analysis of Proteomic and Dermoscopy Imaging Data Improves Noninvasive Classification of Benign Nevi and Melanoma
- 13 November 2024
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 39 (3) , 555-565
In vivo reflectance confocal microscopy role for early to advanced lentigo maligna melanoma spectrum: A systematic review and pooled analysis
Background: Lentigo maligna (LM) is a growing problem worldwide and the main type of melanoma in situ in some Caucasian populations. It presents as a spectrum from atypical intraepidermal melanocytic proliferation (AIMP) to invasive lentigo maligna melanoma (LMM). Accurate diagnosis and staging are crucial for determining appropriate management strategies.Objectives: To assess the role of in vivo reflectance confocal microscopy (RCM) in differentiating early and advanced stages of lentigo maligna.Methods: A systematic search was conducted on Medline, PubMed, Scopus, Web of Science, Proquest Central, Embase, Cochrane and Google Scholar. References of included and excluded studies were reviewed for additional sources. Studies involving RCM for AIMP, LM and LMM diagnosis published until 1 December 2023, were selected for analysis. Publications on other non‐invasive imaging techniques, other skin diseases or those addressing only RCM surgical margins and therapeutic response without reporting RCM features were excluded. Each article was reviewed by two experts, with disagreements resolved by a third expert. Data for each RCM feature were pooled, and odds ratios (ORs) and 95% confidence intervals (CIs) were calculated. Features were stratified for architecture, cellular morphology and distribution.Results: Twenty‐seven articles involving 303 lesions were included. Features favouring LM over AIMP included (1) Architecture: the presence of non‐edged papillae (OR 4.50, 95% CI 1.92–10.52) and (2) Cellular distribution: widespread pagetoid cells and junctional atypical cells (OR 25.06, 95% CI 4.19–148.45) and junctional nests (OR 18.06, 95% CI 3.04–106.32). Features favouring LMM over LM included (1) Architecture: epidermal disarray (OR 5.03, 95% CI 1.90–13.22), junctional disarray (OR 4.19, 95% CI 1.54–11.33) and destroyed collagen fibres (OR 3.91, 95% CI 1.80–8.44) and (2) cellular distribution: widespread pagetoid and junctional atypical cells (OR 2.71, 95% CI 1.27–5.75) and junctional nests (OR 4.48, 95% CI 2.12–9.43).Conclusions: This study identifies the RCM features associated with the LM/LMM spectrum.
- 13 November 2024
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 39 (3) , 555-565
In vivo reflectance confocal microscopy role for early to advanced lentigo maligna melanoma spectrum: A systematic review and pooled analysis
Background: Lentigo maligna (LM) is a growing problem worldwide and the main type of melanoma in situ in some Caucasian populations. It presents as a spectrum from atypical intraepidermal melanocytic proliferation (AIMP) to invasive lentigo maligna melanoma (LMM). Accurate diagnosis and staging are crucial for determining appropriate management strategies.Objectives: To assess the role of in vivo reflectance confocal microscopy (RCM) in differentiating early and advanced stages of lentigo maligna.Methods: A systematic search was conducted on Medline, PubMed, Scopus, Web of Science, Proquest Central, Embase, Cochrane and Google Scholar. References of included and excluded studies were reviewed for additional sources. Studies involving RCM for AIMP, LM and LMM diagnosis published until 1 December 2023, were selected for analysis. Publications on other non‐invasive imaging techniques, other skin diseases or those addressing only RCM surgical margins and therapeutic response without reporting RCM features were excluded. Each article was reviewed by two experts, with disagreements resolved by a third expert. Data for each RCM feature were pooled, and odds ratios (ORs) and 95% confidence intervals (CIs) were calculated. Features were stratified for architecture, cellular morphology and distribution.Results: Twenty‐seven articles involving 303 lesions were included. Features favouring LM over AIMP included (1) Architecture: the presence of non‐edged papillae (OR 4.50, 95% CI 1.92–10.52) and (2) Cellular distribution: widespread pagetoid cells and junctional atypical cells (OR 25.06, 95% CI 4.19–148.45) and junctional nests (OR 18.06, 95% CI 3.04–106.32). Features favouring LMM over LM included (1) Architecture: epidermal disarray (OR 5.03, 95% CI 1.90–13.22), junctional disarray (OR 4.19, 95% CI 1.54–11.33) and destroyed collagen fibres (OR 3.91, 95% CI 1.80–8.44) and (2) cellular distribution: widespread pagetoid and junctional atypical cells (OR 2.71, 95% CI 1.27–5.75) and junctional nests (OR 4.48, 95% CI 2.12–9.43).Conclusions: This study identifies the RCM features associated with the LM/LMM spectrum.
- Open Access
- 20 December 2022
- Published by JMIR Publications Inc. in JMIR Dermatology
- Vol. 5 (4) , e40623
Perspectives and Experiences of Patient-Led Melanoma Surveillance Using Digital Technologies From Clinicians Involved in the MEL-SELF Pilot Randomized Controlled Trial: Qualitative Interview Study
Background: The growing number of melanoma patients who need long-term surveillance increasingly exceeds the capacity of the dermatology workforce, particularly outside of metropolitan areas. Digital technologies that enable patients to perform skin self-examination and send dermoscopic images of lesions of concern to a dermatologist (mobile teledermoscopy) are a potential solution. If these technologies and the remote delivery of melanoma surveillance are to be incorporated into routine clinical practice, they need to be accepted by clinicians providing melanoma care, such as dermatologists and general practitioners (GPs). Objective: This study aimed to explore perceptions of potential benefits and harms of mobile teledermoscopy, as well as experiences with this technology, among clinicians participating in a pilot randomized controlled trial (RCT) of patient-led melanoma surveillance. Methods: This qualitative study was nested within a pilot RCT conducted at dermatologist and skin specialist GP–led melanoma clinics in New South Wales, Australia. We conducted semistructured interviews with 8 of the total 11 clinicians who were involved in the trial, including 4 dermatologists (3 provided teledermatology, 2 were treating clinicians), 1 surgical oncologist, and 3 GPs with qualifications in skin cancer screening (the remaining 3 GPs declined an interview). Thematic analysis was used to analyze the data with reference to the concepts of “medical overuse” and “high-value care.” Results: Clinicians identified several potential benefits, including increased access to dermatology services, earlier detection of melanomas, reassurance for patients between scheduled visits, and a reduction in unnecessary clinic visits. However, they also identified some potential concerns regarding the use of the technology and remote monitoring that could result in diagnostic uncertainty. These included poor image quality, difficulty making assessments from a 2D digital image (even if good quality), insufficient clinical history provided, and concern that suspicious lesions may have been missed by the patient. Clinicians thought that uncertainty arising from these concerns, together with perceived potential medicolegal consequences from missing a diagnosis, might lead to increases in unnecessary clinic visits and procedures. Strategies suggested for achieving high-value care included managing clinical uncertainty to decrease the potential for medical overuse and ensuring optimal placement of patient-led teledermoscopy within existing clinical care pathways to increase the potential for benefits. Conclusions: Clinicians were enthusiastic about the potential and experienced benefits of mobile teledermoscopy; however, managing clinical uncertainty will be necessary to achieve these benefits in clinical care outside of trial contexts and minimize potential harms from medical overuse. Trial Registration: Australian and New Zealand Clinical Trials Registry ACTRN12616001716459; https://anzctr.org.au/Trial/Registration/TrialReview.aspx?id=371865
- 20 December 2022
- Published by JMIR Publications Inc. in JMIR Dermatology
- Vol. 5 (4) , e40623
Open AccessPerspectives and Experiences of Patient-Led Melanoma Surveillance Using Digital Technologies From Clinicians Involved in the MEL-SELF Pilot Randomized Controlled Trial: Qualitative Interview Study
Background: The growing number of melanoma patients who need long-term surveillance increasingly exceeds the capacity of the dermatology workforce, particularly outside of metropolitan areas. Digital technologies that enable patients to perform skin self-examination and send dermoscopic images of lesions of concern to a dermatologist (mobile teledermoscopy) are a potential solution. If these technologies and the remote delivery of melanoma surveillance are to be incorporated into routine clinical practice, they need to be accepted by clinicians providing melanoma care, such as dermatologists and general practitioners (GPs). Objective: This study aimed to explore perceptions of potential benefits and harms of mobile teledermoscopy, as well as experiences with this technology, among clinicians participating in a pilot randomized controlled trial (RCT) of patient-led melanoma surveillance. Methods: This qualitative study was nested within a pilot RCT conducted at dermatologist and skin specialist GP–led melanoma clinics in New South Wales, Australia. We conducted semistructured interviews with 8 of the total 11 clinicians who were involved in the trial, including 4 dermatologists (3 provided teledermatology, 2 were treating clinicians), 1 surgical oncologist, and 3 GPs with qualifications in skin cancer screening (the remaining 3 GPs declined an interview). Thematic analysis was used to analyze the data with reference to the concepts of “medical overuse” and “high-value care.” Results: Clinicians identified several potential benefits, including increased access to dermatology services, earlier detection of melanomas, reassurance for patients between scheduled visits, and a reduction in unnecessary clinic visits. However, they also identified some potential concerns regarding the use of the technology and remote monitoring that could result in diagnostic uncertainty. These included poor image quality, difficulty making assessments from a 2D digital image (even if good quality), insufficient clinical history provided, and concern that suspicious lesions may have been missed by the patient. Clinicians thought that uncertainty arising from these concerns, together with perceived potential medicolegal consequences from missing a diagnosis, might lead to increases in unnecessary clinic visits and procedures. Strategies suggested for achieving high-value care included managing clinical uncertainty to decrease the potential for medical overuse and ensuring optimal placement of patient-led teledermoscopy within existing clinical care pathways to increase the potential for benefits. Conclusions: Clinicians were enthusiastic about the potential and experienced benefits of mobile teledermoscopy; however, managing clinical uncertainty will be necessary to achieve these benefits in clinical care outside of trial contexts and minimize potential harms from medical overuse. Trial Registration: Australian and New Zealand Clinical Trials Registry ACTRN12616001716459; https://anzctr.org.au/Trial/Registration/TrialReview.aspx?id=371865
- Open Access
- 30 June 2022
- Published by JMIR Publications Inc. in JMIR Preprints
Perspectives and experiences of patient-led melanoma surveillance using digital technologies from clinicians involved in the MEL-SELF pilot randomised controlled trial: Qualitative Interview Study (Preprint)
BACKGROUND The large and growing number of melanoma patients who need long term surveillance increasingly exceeds capacity of the dermatology workforce, particularly outside of metropolitan areas. Digital technologies that enable patients to do skin self-examination and send dermoscopic images of lesions of concern to a dermatologist (mobile teledermoscopy) are one potential solution. If these technologies and the remote delivery of melanoma surveillance are to be incorporated into routine clinical practice, they need to be accepted by clinicians providing melanoma care (e.g., dermatologists and general practitioners (GPs)). OBJECTIVE To explore perceptions of potential benefits and harms of mobile teledermoscopy, and experiences with this technology, among clinicians participating in a pilot randomised controlled trial (RCT) of patient-led melanoma surveillance. METHODS This qualitative study was nested within a pilot RCT conducted at dermatologist- and skin specialist GP-led melanoma clinics in New South Wales, Australia. We conducted semi-structured interviews with 8 of the total 11 clinicians who were involved in the trial: 4 dermatologists (3 provided teledermatology, 2 were treating clinicians), 1 surgical oncologist, and 3 GPs with qualifications in skin cancer screening (the remaining 3 GPs declined interview). Thematic analysis was used to analyse the data with reference to concepts ‘medical overuse’ and ‘high-value care’. RESULTS Clinicians identified several potential benefits, including increased access to dermatology services, earlier detection of melanomas, reassurance for patients between scheduled visits, and a reduction in unnecessary clinic visits. However, they also identified some potential concerns around use of the technology and remote monitoring that could result in diagnostic uncertainty. These included poor image quality, difficulty making assessments from a 2D digital image (even if good quality), insufficient clinical history provided, and concern that suspicious lesions may have been missed by the patient. Clinicians thought that uncertainty arising from these concerns, together with perceived potential medico-legal consequences from missing a diagnosis, might lead to increases in unnecessary clinic visits and procedures. Strategies suggested for achieving high-value care included managing clinical uncertainty in order to decrease the potential for medical overuse, and by ensuring optimal placement of patient-led teledermoscopy within existing clinical care pathways to increase the potential for benefits. CONCLUSIONS Clinicians were enthusiastic about the potential and experienced benefits of mobile teledermoscopy; however, managing clinical uncertainty will be necessary to achieve these benefits in clinical care outside of trial contexts, and to minimise potential harms from medical overuse.
- 30 June 2022
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessPerspectives and experiences of patient-led melanoma surveillance using digital technologies from clinicians involved in the MEL-SELF pilot randomised controlled trial: Qualitative Interview Study (Preprint)
BACKGROUND The large and growing number of melanoma patients who need long term surveillance increasingly exceeds capacity of the dermatology workforce, particularly outside of metropolitan areas. Digital technologies that enable patients to do skin self-examination and send dermoscopic images of lesions of concern to a dermatologist (mobile teledermoscopy) are one potential solution. If these technologies and the remote delivery of melanoma surveillance are to be incorporated into routine clinical practice, they need to be accepted by clinicians providing melanoma care (e.g., dermatologists and general practitioners (GPs)). OBJECTIVE To explore perceptions of potential benefits and harms of mobile teledermoscopy, and experiences with this technology, among clinicians participating in a pilot randomised controlled trial (RCT) of patient-led melanoma surveillance. METHODS This qualitative study was nested within a pilot RCT conducted at dermatologist- and skin specialist GP-led melanoma clinics in New South Wales, Australia. We conducted semi-structured interviews with 8 of the total 11 clinicians who were involved in the trial: 4 dermatologists (3 provided teledermatology, 2 were treating clinicians), 1 surgical oncologist, and 3 GPs with qualifications in skin cancer screening (the remaining 3 GPs declined interview). Thematic analysis was used to analyse the data with reference to concepts ‘medical overuse’ and ‘high-value care’. RESULTS Clinicians identified several potential benefits, including increased access to dermatology services, earlier detection of melanomas, reassurance for patients between scheduled visits, and a reduction in unnecessary clinic visits. However, they also identified some potential concerns around use of the technology and remote monitoring that could result in diagnostic uncertainty. These included poor image quality, difficulty making assessments from a 2D digital image (even if good quality), insufficient clinical history provided, and concern that suspicious lesions may have been missed by the patient. Clinicians thought that uncertainty arising from these concerns, together with perceived potential medico-legal consequences from missing a diagnosis, might lead to increases in unnecessary clinic visits and procedures. Strategies suggested for achieving high-value care included managing clinical uncertainty in order to decrease the potential for medical overuse, and by ensuring optimal placement of patient-led teledermoscopy within existing clinical care pathways to increase the potential for benefits. CONCLUSIONS Clinicians were enthusiastic about the potential and experienced benefits of mobile teledermoscopy; however, managing clinical uncertainty will be necessary to achieve these benefits in clinical care outside of trial contexts, and to minimise potential harms from medical overuse.
- Open Access
- 15 February 2022
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 47 (5) , 932-941
Dermoscopic features and screening strategies for the detection of small‐diameter melanomas
Background If 70% of cutaneous melanomas develop de novo, small-diameter or tiny lesions are expected to represent the earliest manifestation of most melanomas. Objectives To describe the clinical, histopathological and dermoscopic features of tiny melanomas; and to investigate the impact of imaging tools, including total body photography (TBP) and sequential digital dermoscopy imaging (SDDI) in their detection. Methods Consecutive melanomas diagnosed over 2 years in a referral centre were retrospectively included. Diameter ≤5mm on dermoscopy defined tiny melanomas. Dermoscopic features and performance of four methods were evaluated. Results 86/312 (27.6%) of the included melanomas measured ≤5mm. They were invasive in 44.2%. Tiny melanomas were more frequently excised for being new and/or changing compared to non-tiny melanomas (77.9% vs. 50.9%; P<.0001). Half of the tiny melanomas would have been missed by the dermoscopic 7-point checklist (48.2%) or the 3-point checklist (49.4%). Menzies’ method and the revised pattern analysis correctly identified respectively 65.9% and 63.5% of the tiny melanomas. The most frequent positive features for tiny melanomas were asymmetry in structure or colour (77.6%), brown dots (65.9%), irregular dots and globules (76.5%) and atypical pigment network (44.7%). Dermoscopic features predictive of invasion in tiny melanomas were (OR, 95%CI) atypical vascular pattern (26.5, 1.5-475.5, P=.002), shiny white lines (12.4, 0.7-237.8, P=0.04) and grey/blue structures (3.7, 1.3-10.5, P=0.01). Conclusions Tiny melanomas are frequently invasive and represent a clinical, dermoscopic and histopathological challenge. Dermoscopy alone has suboptimal diagnostic accuracy. Early diagnosis relies on the detection of new or changing lesions aided by TBP and SDDI.
- 15 February 2022
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 47 (5) , 932-941
Open AccessDermoscopic features and screening strategies for the detection of small‐diameter melanomas
Background If 70% of cutaneous melanomas develop de novo, small-diameter or tiny lesions are expected to represent the earliest manifestation of most melanomas. Objectives To describe the clinical, histopathological and dermoscopic features of tiny melanomas; and to investigate the impact of imaging tools, including total body photography (TBP) and sequential digital dermoscopy imaging (SDDI) in their detection. Methods Consecutive melanomas diagnosed over 2 years in a referral centre were retrospectively included. Diameter ≤5mm on dermoscopy defined tiny melanomas. Dermoscopic features and performance of four methods were evaluated. Results 86/312 (27.6%) of the included melanomas measured ≤5mm. They were invasive in 44.2%. Tiny melanomas were more frequently excised for being new and/or changing compared to non-tiny melanomas (77.9% vs. 50.9%; P<.0001). Half of the tiny melanomas would have been missed by the dermoscopic 7-point checklist (48.2%) or the 3-point checklist (49.4%). Menzies’ method and the revised pattern analysis correctly identified respectively 65.9% and 63.5% of the tiny melanomas. The most frequent positive features for tiny melanomas were asymmetry in structure or colour (77.6%), brown dots (65.9%), irregular dots and globules (76.5%) and atypical pigment network (44.7%). Dermoscopic features predictive of invasion in tiny melanomas were (OR, 95%CI) atypical vascular pattern (26.5, 1.5-475.5, P=.002), shiny white lines (12.4, 0.7-237.8, P=0.04) and grey/blue structures (3.7, 1.3-10.5, P=0.01). Conclusions Tiny melanomas are frequently invasive and represent a clinical, dermoscopic and histopathological challenge. Dermoscopy alone has suboptimal diagnostic accuracy. Early diagnosis relies on the detection of new or changing lesions aided by TBP and SDDI.
- 18 January 2022
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 36 (6) , E445-E448
Successful treatment of eruptive keratoacanthomas with actitretin for patients on checkpoint inhibitor immunotherapy
- 18 January 2022
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 36 (6) , E445-E448
Successful treatment of eruptive keratoacanthomas with actitretin for patients on checkpoint inhibitor immunotherapy
- 27 January 2021
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 35 (6) , 1315-1322
Lentiginous melanoma (lentigo maligna and lentigo maligna melanoma) in Australia: clinicopathological characteristics, management and recurrence rates after 10‐year follow‐up at a tertiary centre
Background: Lentiginous melanoma or lentigo maligna is a slow‐growing type of melanoma frequently arising in sun‐damaged skin and often first diagnosed in the elderly. Few studies report long‐term follow‐up.Objectives: To define characteristics of lentiginous melanoma in situ (LM) and invasive lentiginous melanoma (LMM) in Australian patients managed at a tertiary centre and describe local recurrence or treatment failure rates after long‐term follow‐up.Methods: Retrospective single‐centre study of LM/LMM patients evaluated between January 2005 and March 2007. Medical and photographic records were reviewed.Results: One hundred two patients were included, with a total of 117 lesions (70 LM and 47 LMM). Seventy‐nine were new primary LM/LMM, and 38 were recurrences. Primary cases were mostly pigmented (71%), while 77% of recurrent cases were partially pigmented/light brown or amelanotic. The margins were clinically ill‐defined in the majority of cases (64% of primary cases and 94% of recurrent cases). Dermoscopy of the primary LM/LMM showed either classic ‘common’ melanoma features (33%) or classic LM/LMM features (41%), while 95% of recurrent cases had no features for melanoma or LM/LMM. Primary cases that were initially excised (113, 97%) had mean histopathological clear margins of 4.9 mm (range 0.1–22 mm). The median follow‐up time was 7.5 years (95% CI 5.2–10.0) with more than 10‐year follow‐up in 32% and 5–10 years in 24% of patients. There were 44 (38%) recurrences over the entire follow‐up period. Half of the patients who recurred did so within the first 3.8 years after the first treatment.Conclusion: LM/LMM often recur late and are clinically subtle; therefore, careful monitoring and long‐term follow‐up are required.
- 27 January 2021
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 35 (6) , 1315-1322
Lentiginous melanoma (lentigo maligna and lentigo maligna melanoma) in Australia: clinicopathological characteristics, management and recurrence rates after 10‐year follow‐up at a tertiary centre
Background: Lentiginous melanoma or lentigo maligna is a slow‐growing type of melanoma frequently arising in sun‐damaged skin and often first diagnosed in the elderly. Few studies report long‐term follow‐up.Objectives: To define characteristics of lentiginous melanoma in situ (LM) and invasive lentiginous melanoma (LMM) in Australian patients managed at a tertiary centre and describe local recurrence or treatment failure rates after long‐term follow‐up.Methods: Retrospective single‐centre study of LM/LMM patients evaluated between January 2005 and March 2007. Medical and photographic records were reviewed.Results: One hundred two patients were included, with a total of 117 lesions (70 LM and 47 LMM). Seventy‐nine were new primary LM/LMM, and 38 were recurrences. Primary cases were mostly pigmented (71%), while 77% of recurrent cases were partially pigmented/light brown or amelanotic. The margins were clinically ill‐defined in the majority of cases (64% of primary cases and 94% of recurrent cases). Dermoscopy of the primary LM/LMM showed either classic ‘common’ melanoma features (33%) or classic LM/LMM features (41%), while 95% of recurrent cases had no features for melanoma or LM/LMM. Primary cases that were initially excised (113, 97%) had mean histopathological clear margins of 4.9 mm (range 0.1–22 mm). The median follow‐up time was 7.5 years (95% CI 5.2–10.0) with more than 10‐year follow‐up in 32% and 5–10 years in 24% of patients. There were 44 (38%) recurrences over the entire follow‐up period. Half of the patients who recurred did so within the first 3.8 years after the first treatment.Conclusion: LM/LMM often recur late and are clinically subtle; therefore, careful monitoring and long‐term follow‐up are required.